Company / Free Cash Flow
Outlook Therapeutics, Inc. Free Cash Flow History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$32.7M
FY2020
5-year range
-$46.6M / -$15.8M
FY2016-FY2020
Trend
+8.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 5 years, ranging from -$47M in FY2017 to -$16M in FY2018.
Based on SEC 10-K filings.
-$33M in FY2020.
Declined from -$16M to -$33M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, free cash flow increased 8.6% year-over-year.
- Peak free cash flow was recorded in FY2018.
- Lowest free cash flow in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2020 | -$32.7M | +8.6% |
| FY2019 | -$35.8M | -126.8% |
| FY2018 | -$15.8M | +66.1% |
| FY2017 | -$46.6M | -28.4% |
| FY2016 | -$36.3M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026